Dr. Burkhart received his medical toxicology training at the Rocky Mountain Poison Center in Denver. He is a Clinical Professor of Emergency Medicine at the Penn State University. Clinical care is provided at the PinnacleHealth Toxicology Center. He is a co-editor of Critical Care Toxicology.
PRESENTER
(S):
J. Steven Leeder, Children's Mercy Hospitals and Clinics, United States
J. Steven Leeder, PharmD, PhD is the Marion Merrell Dow/Missouri Endowed Chair in Pediatric Clinical Pharmacology and Chief, Division of Clinical Pharmacology and Medical Toxicology at Children’s Mercy Hospitals and Clinics in Kansas City, Missouri.
Dr. Burkhart received his medical toxicology training at the Rocky Mountain Poison Center in Denver. He is a Clinical Professor of Emergency Medicine at the Penn State University. Clinical care is provided at the PinnacleHealth Toxicology Center. He is a co-editor of Critical Care Toxicology.
Dr. Whritenour joined the Immunotoxicology Center of Emphasis in Drug Safety Research and Development at Pfizer in 2007. She is working on developing predictive models and diagnostic tools for delayed type drug hypersensitivity reactions and pseudoallergic drug responses.
Description
AERS data mining supports the hypothesis that drugs associated with Stevens Johnson Syndrome (SJS) undergo biotransformation. Reviews of the role of drug metabolism and SJS and preclinical testing for skin hypersensitivity are provided.
Learning Objectives: Describe AERS data mining findings that support a role for skin biotransformation of drugs associated with Stevens Johnson Syndrome (SJS) Review the evidence for drug metabolism in SJS Discuss industry nonclinical testing for skin hypersensitivity and relevance to SJS.